{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:23:25Z","timestamp":1791404605137,"version":"4.3.3"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.vph.2018.10.008","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T11:44:47Z","timestamp":1541159087000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":270,"special_numbering":"C","title":["The first 3500\u202fyears of aspirin history from its roots \u2013 A concise summary"],"prefix":"10.1016","volume":"113","author":[{"given":"Maria Rosa","family":"Montinari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6259-8883","authenticated-orcid":false,"given":"Sergio","family":"Minelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-574X","authenticated-orcid":false,"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2018.10.008_bb0005","series-title":"Aspirin: The Remarkable Story of a Wonder Drug","author":"Jeffreys","year":"2004"},{"key":"10.1016\/j.vph.2018.10.008_bb0010","series-title":"Acetylsalicylic Acid","author":"Schr\u00f6r","year":"2016"},{"key":"10.1016\/j.vph.2018.10.008_bb0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0140-6736(97)07087-6","article-title":"One hundred years of aspirin","volume":"350","author":"Jack","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2018.10.008_bb0020","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/bmj.321.7276.1591","article-title":"The discovery of aspirin: a reappraisal","volume":"321","author":"Sneader","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.vph.2018.10.008_bb0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3121\/cmr.2013.1197","article-title":"The role of aspirin in the prevention of cardiovascular disease","volume":"12","author":"Ittaman","year":"2014","journal-title":"Clin. Med. Res."},{"key":"10.1016\/j.vph.2018.10.008_bb0030","first-page":"370","article-title":"From plant extract to molecular panacea: a commentary on Stone (1763) 'An account of the success of the bark of the willow in the cure of the agues'","author":"Wood","year":"2015","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.vph.2018.10.008_bb0035","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.hoc.2016.06.002","article-title":"The history of antithrombotic therapy: the discovery of heparin, the Vitamin K antagonists, and the utility of aspirin","volume":"30","author":"Handin","year":"2016","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.vph.2018.10.008_bb0040","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s40265-017-0823-0","article-title":"Aspirin for prevention of preeclampsia","volume":"77","author":"Atallah","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.vph.2018.10.008_bb0045","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.14520","article-title":"The aspirin story - from willow to wonder drug","volume":"177","author":"Desborough","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.vph.2018.10.008_bb0050","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1186\/s12885-017-3757-8","article-title":"Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials","volume":"17","author":"Veettil","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.vph.2018.10.008_bb0055","series-title":"Murder, Magic and Medicine","author":"Mann","year":"1992"},{"key":"10.1016\/j.vph.2018.10.008_bb0060","series-title":"The Papyrus Ebers","author":"Bryan","year":"1931"},{"key":"10.1016\/j.vph.2018.10.008_bb0065","first-page":"195","article-title":"An account of the success of the bark of the willow in the cure of agues","volume":"53","author":"Stone","year":"1763","journal-title":"Phil Trans"},{"key":"10.1016\/j.vph.2018.10.008_bb0070","first-page":"66","article-title":"The Italian contributions to the history of salicylates","volume":"58","author":"Marson","year":"2006","journal-title":"Reumatismo"},{"key":"10.1016\/j.vph.2018.10.008_bb0075","series-title":"La salicina, principio medicamentoso del salice bianco (Salix alba. o base vegetale salificabile). Giornale di Farmacia-Chimica e Scienze Accessorie o sia Raccolta delle scoperte, ritrovati e miglioramenti fatti in Farmacia ed in Chimica","first-page":"644","volume":"vol. 1","author":"Fontana","year":"1824"},{"key":"10.1016\/j.vph.2018.10.008_bb0080","first-page":"267","article-title":"Sostituto indigeno del solfato di chinina","volume":"33","author":"Rigatelli","year":"1824","journal-title":"Biblioteca Italiana o sia Giornale di Letteratura, Scienze ed Arti"},{"key":"10.1016\/j.vph.2018.10.008_bb0085","first-page":"173","article-title":"Salino amarissimo antifebbrile","volume":"4","author":"Rigatelli","year":"1826","journal-title":"Giornale di Farmacia-Chimica e Scienze Accessorie o siano Annali Universali delle scoperte, ritrovati e miglioramenti fatti in Farmacia ed in Chimica"},{"key":"10.1016\/j.vph.2018.10.008_bb0090","series-title":"Aspirin and Other Salicylates","author":"Vane","year":"1992"},{"key":"10.1016\/j.vph.2018.10.008_bb0095","first-page":"341","article-title":"D\u00e9couvert de la salicine","volume":"6","author":"Leroux","year":"1830","journal-title":"J de Chimie Medicale"},{"key":"10.1016\/j.vph.2018.10.008_bb0100","unstructured":"Piria R. Sur la composition de la salicine et quelques-unes de ses r\u00e9actions. Comptes Rendues de l'Academie des Sciences, Paris 1838;6:338."},{"key":"10.1016\/j.vph.2018.10.008_bb0105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF02729196","article-title":"Sulle alterazioni che alcuni acidi subiscono nell'organismo animale","author":"Bertagnini","year":"1855","journal-title":"Il Nuovo Cimento, Tipografia Pieraccini, Pisa"},{"key":"10.1016\/j.vph.2018.10.008_bb0110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jlac.18530870206","article-title":"Untersuchungen \u00fcber die wasserfreien organischen S\u00e4uren","volume":"87","author":"Gerhardt","year":"1853","journal-title":"Liebigs Ann."},{"key":"10.1016\/j.vph.2018.10.008_bb0115","series-title":"Drug discovery - a history","author":"Sneader","year":"2005"},{"key":"10.1016\/j.vph.2018.10.008_bb0120","first-page":"1","article-title":"Aus der Traubschen Klinik. \u00dcber die Resultate der Behandlung des Polyarthritis rheumatica mit Salicyls\u00e4ure","volume":"13","author":"Stricker","year":"1976","journal-title":"Berl Klin Wochenschr"},{"key":"10.1016\/j.vph.2018.10.008_bb0125","first-page":"86","article-title":"Nachtrag zur Anwendung der Salicyls\u00e4ure bei dem akuten Gelenkrheumatismus","volume":"13","author":"Reiss","year":"1876","journal-title":"Berl Klin Wochenschr"},{"key":"10.1016\/j.vph.2018.10.008_bb0130","first-page":"342","article-title":"The treatment of acute rheumatism by salicin","volume":"4","author":"Mac","year":"1876","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2018.10.008_bb0135","series-title":"Traitement du rhumatisme, de la goutte aigue et chronique et de diverses affectiom du systeme nerveux par le salicylate de soude","author":"S\u00e9e","year":"1877"},{"key":"10.1016\/j.vph.2018.10.008_bb0140","series-title":"Memorie dell'Accademia delle Scienze dell'Istituto di Bologna, Serie Terza, Tomo IX Tipi Gamberini e Parmeggiani, Bologna","first-page":"477","article-title":"Il salicilato di soda considerato quale specifico nella cura del reumatismo articolare acuto","author":"Brugnoli","year":"1878"},{"key":"10.1016\/j.vph.2018.10.008_bb0145","series-title":"Aspirin 100 Years: The Future Has Just Begun","author":"Zundorf","year":"1997"},{"key":"10.1016\/j.vph.2018.10.008_bb0150","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01662127","article-title":"Pharmacologisches \u00fcber Aspirin (Acetylsalicyls\u00e4ure)","volume":"76","author":"Dreser","year":"1899","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.vph.2018.10.008_bb0155","first-page":"396","article-title":"Aspirin, ein neues Salicylpr\u00e4parat","volume":"3","author":"Witthauer","year":"1899","journal-title":"Die Heilkunde"},{"key":"10.1016\/j.vph.2018.10.008_bb0160","first-page":"276","article-title":"\u00dcber Aspirin (Acetylsalicyls\u00e4ure)","author":"Wohlgemut","year":"1899","journal-title":"Therap Mschr"},{"key":"10.1016\/j.vph.2018.10.008_bb0165","first-page":"641","article-title":"An experimental study of aspirin, a new salicylic acid preparation","volume":"75","author":"Floeckinger","year":"1899","journal-title":"Med News"},{"key":"10.1016\/j.vph.2018.10.008_bb0170","first-page":"582","article-title":"50 Jahre Aspirin","volume":"4","author":"Eichengr\u00fcn","year":"1949","journal-title":"Die Pharmazie"},{"key":"10.1016\/j.vph.2018.10.008_bb0175","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1136\/bmj.329.7479.1408","article-title":"Aspirin: the Story of a Wonder Drug","volume":"329","author":"Lichtermann","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.vph.2018.10.008_bb0180","series-title":"Drugs and Medicinal Preparations: Vsesojuzno e Objedmnenije","author":"Mashkovsky","year":"1958"},{"key":"10.1016\/j.vph.2018.10.008_bb0185","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1476-5381.1960.tb00288.x","article-title":"Analgesic antipyretic drugs as antagonists of bradykinin","volume":"15","author":"Collier","year":"1960","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"10.1016\/j.vph.2018.10.008_bb0190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/223029a0","article-title":"Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs","volume":"223","author":"Piper","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.vph.2018.10.008_bb0195","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat. New Biol."},{"key":"10.1016\/j.vph.2018.10.008_bb0200","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1073\/pnas.72.8.2994","article-title":"Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides","volume":"72","author":"Hamberg","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.vph.2018.10.008_bb0205","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1016\/S0021-9258(17)33098-3","article-title":"Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme","volume":"251","author":"Hemler","year":"1976","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2018.10.008_bb0210","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1073\/pnas.72.8.3073","article-title":"Acetylation of prostaglandin synthase by aspirin","volume":"72","author":"Roth","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.vph.2018.10.008_bb0215","doi-asserted-by":"crossref","first-page":"13207","DOI":"10.1016\/S0021-9258(17)36820-5","article-title":"Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin","volume":"269","author":"Lecomte","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2018.10.008_bb0220","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(68)90046-9","article-title":"Bleeding time after aspirin ingestion","volume":"1","author":"Quick","year":"1968","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2018.10.008_bb0225","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/194927b0","article-title":"Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal","volume":"194","author":"Born","year":"1962","journal-title":"Nature"},{"key":"10.1016\/j.vph.2018.10.008_bb0230","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/0002-9343(83)90522-3","article-title":"The biologic background to some therapeutic uses of aspirin","volume":"74","author":"Born","year":"1983","journal-title":"Am. J. Med."},{"key":"10.1016\/j.vph.2018.10.008_bb0235","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1172\/JCI105903","article-title":"The effect of salicylates on the hemostatic properties of platelets in man","volume":"47","author":"Weiss","year":"1968","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2018.10.008_bb0240","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1084\/jem.128.5.877","article-title":"The effect of acetylsalicyclic acid on platelet function","volume":"128","author":"Evans","year":"1968","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.vph.2018.10.008_bb0245","first-page":"513","article-title":"Pharmacology of blood platelet aggregation","volume":"9","author":"Born","year":"1969","journal-title":"Nouv. Rev. Fr. Hematol."},{"key":"10.1016\/j.vph.2018.10.008_bb0250","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2018.10.008_bb0255","first-page":"259","article-title":"Low-dose aspirin is a selective inhibitor of platelet cyclooxygenase activity in healthy subjects","volume":"11","author":"Patrignani","year":"1983","journal-title":"Adv. Prostaglandin Thromboxane Leukot. Res."},{"key":"10.1016\/j.vph.2018.10.008_bb0260","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0002-9149(85)90258-9","article-title":"Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction","volume":"55","author":"De Caterina","year":"1985","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.vph.2018.10.008_bb0265","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/oxfordjournals.eurheartj.a061879","article-title":"Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function","volume":"6","author":"De Caterina","year":"1985","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2018.10.008_bb0270","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","article-title":"Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis","volume":"70","author":"Patrono","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2018.10.008_bb0275","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.prostaglandins.2015.07.004","article-title":"Aspirin and lipid mediators in the cardiovascular system","volume":"121","author":"Schror","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.vph.2018.10.008_bb0280","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10555-017-9675-z","article-title":"Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention","volume":"36","author":"Ornelas","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.vph.2018.10.008_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(02)01828-9","article-title":"Anti-inflammatory effects of aspirin and sodium salicylate","volume":"447","author":"Amann","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.vph.2018.10.008_bb0290","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2012.11.018","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2018.10.008_bb0295","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2018.10.008_bb0300","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2018.10.008_bb0305","volume":"2017","author":"Ibanez","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2018.10.008_bb0310","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0021-9258(18)72399-5","article-title":"Studies on hemorrhagic sweet clover disease","volume":"147","author":"Link","year":"1949","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2018.10.008_bb0315","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archotol.1945.00680040033004","article-title":"Acetylsalicylic acid, a probable cause for secondary post-tonsillectomy hemorrhage","volume":"42","author":"Singer","year":"1949","journal-title":"Arch. Otolaryngol."},{"key":"10.1016\/j.vph.2018.10.008_bb0320","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S0140-6736(49)91829-2","article-title":"Aspirin in the treatment of vascular diseases","volume":"2","author":"Gibson","year":"1949","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2018.10.008_bb0325","first-page":"38","article-title":"Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis","volume":"75","author":"Craven","year":"1953","journal-title":"Miss Valley Med. J."},{"key":"10.1016\/j.vph.2018.10.008_bb0330","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jacc.2014.03.049","article-title":"Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis","volume":"64","author":"Halvorsen","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2018.10.008_bb0335","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.vph.2018.10.008_bb0340","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/bmj.1.5905.436","article-title":"A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction","volume":"1","author":"Elwood","year":"1974","journal-title":"Br. Med. J."},{"key":"10.1016\/j.vph.2018.10.008_bb0345","first-page":"1172","article-title":"Aspirin after myocardial infarction","volume":"1","author":"Peto","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2018.10.008_bb0350","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study","volume":"309","author":"Lewis","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2018.10.008_bb0355","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2018.10.008_bb0360","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJM197807132990201","volume":"299","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2018.10.008_bb0365","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199110313251801","article-title":"A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke","volume":"325","author":"van Gijn","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2018.10.008_bb0370","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/0140-6736(91)92233-R","volume":"338","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2018.10.008_bb0375","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10152","key":"10.1016\/j.vph.2018.10.008_bb0380","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2018.10.008_bb0385","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2018.10.008_bb0390","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2018.10.008_bb0395","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/CIRCULATIONAHA.117.028321","article-title":"Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort study","volume":"136","author":"Sundstr\u00f6m","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2018.10.008_bb0400","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.vph.2018.10.008_bb0405","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajog.2017.11.561","article-title":"Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis","volume":"218","author":"Roberge","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.vph.2018.10.008_bb0410","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","article-title":"Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials","volume":"392","author":"Rothwell","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2018.10.008_bb0415","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2018.10.008_bb0420","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/B978-0-7020-4086-3.00038-2","article-title":"Nonsteroidal anti-inflammatory drugs exposure and the central nervous system","volume":"119","author":"Auriel","year":"2014","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.vph.2018.10.008_bb0425","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jacc.2016.05.083","article-title":"Aspirin and Cancer","volume":"68","author":"Patrignani","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2018.10.008_bb0430","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","article-title":"Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials","volume":"13","author":"Algra","year":"2012","journal-title":"Lancet Oncol."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189118303549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189118303549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:17:50Z","timestamp":1761527870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189118303549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":86,"alternative-id":["S1537189118303549"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2018.10.008","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The first 3500\u202fyears of aspirin history from its roots \u2013 A concise summary","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2018.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}